Global Leading Market Research Publisher QYResearch announces the release of its latest report "Defibrinated Horse Blood - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032". Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Defibrinated Horse Blood market, including market size, share, demand, industry development status, and forecasts for the next few years.

For microbiology laboratories, clinical diagnostic facilities, and biomedical research institutions, preparing enrichment media for the cultivation of fastidious and demanding microorganisms requires high-quality, consistent blood products free from fibrin clots. The global Defibrinated Horse Blood market addresses this need through mechanically defibrinated, sterile horse blood that provides reliable performance for microbiology diagnostics and research. As infectious disease testing and bacteriology workflows expand globally, demand for defibrinated horse blood continues to grow steadily.

The global market for Defibrinated Horse Blood was estimated to be worth US$ 89.91 million in 2025 and is projected to reach US$ 143 million, growing at a CAGR of 6.9% from 2026 to 2032. In 2024, global production reached 672.019 kiloliters, with an average selling price of US$ 135.16 per liter. This steady growth reflects consistent demand from clinical diagnostics and pharmaceutical quality control laboratories.

【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6097330/defibrinated-horse-blood

Essential Blood Product for Microbiology Culture Media
Defibrinated horse blood is a high-quality, sterile blood product designed for microbiology laboratories. It is essential for preparing enrichment media, particularly for the cultivation of a wide range of demanding microorganisms. Mechanically defibrated, this blood remains free of fibrin clots, providing consistent performance in microbiology diagnostics and research.

The defibrination process removes fibrin through mechanical agitation, preventing clot formation and ensuring uniform distribution of blood components in culture media. Horse blood is preferred for certain applications due to its large red blood cells and specific growth factor composition that supports fastidious organisms. Common applications include preparation of blood agar plates, chocolate agar, and specialized enrichment broths for pathogens such as Streptococcus, Haemophilus, and Neisseria species.

Industry Segmentation: Packaging Sizes & Applications
The Defibrinated Horse Blood market is segmented by container volume and end-use setting:

50ml: Small-volume bottles for research laboratories with limited throughput or specialized applications. A university microbiology lab recently standardized on 50ml defibrinated horse blood for student teaching laboratories.

100ml: Common size for clinical diagnostic laboratories performing routine culture and sensitivity testing.

250ml: Mid-volume size for hospital microbiology departments and regional reference laboratories.

500ml: Large-volume bottles for high-throughput clinical laboratories, pharmaceutical quality control, and industrial microbiology.

Others: Custom volumes for specialized applications.

Application Segments
Biomedicine: Clinical diagnostic microbiology, hospital laboratories, and reference laboratories use defibrinated horse blood for pathogen culture from patient specimens. A regional hospital network reported annual consumption of over 500 liters of defibrinated horse blood across its microbiology departments.

Research: Pharmaceutical R&D, academic research, and veterinary diagnostic laboratories utilize defibrinated horse blood for bacterial culture, antibiotic susceptibility testing, and vaccine development.

Technology Developments & Quality Standards
Over the past six months, several developments have shaped the market. Improved collection and processing protocols have enhanced batch-to-batch consistency for large-volume users. Extended shelf-life formulations (up to 2 years) have reduced waste for lower-volume laboratories. Sterility testing and quality control documentation have become more stringent, with suppliers providing certificates of analysis for each lot.

The trend toward laboratory consolidation and centralized microbiology services has increased demand for larger packaging sizes and consistent supply. Regulatory requirements for culture media quality control (CLSI, ISO standards) drive demand for validated blood products. Animal welfare and sourcing transparency have become considerations for some institutional purchasers.

Regional Market Dynamics
North America leads the defibrinated horse blood market, driven by high clinical microbiology testing volumes and strong pharmaceutical quality control requirements. The United States dominates with significant hospital and reference laboratory demand.

Europe follows closely, with strong microbiology infrastructure in Germany, France, and the UK, and regulatory requirements for culture media quality. Asia-Pacific is the fastest-growing region, with expanding clinical laboratory networks, increasing infectious disease testing, and growing pharmaceutical manufacturing in China, India, and Southeast Asia.

Competitive Landscape
Key players include Thermo Fisher Scientific, TCS Biosciences, BioMérieux, E & O Laboratories Ltd, Southern Biological, Biowest (BioNordic A/S), Pel-Freez Biologicals, Trafalgar Scientific, HemoStat Laboratories, EWC Diagnostics, Dutscher, Serana Europe, Kraeber & Co. GmbH, Bio Nutrientes Do Brasil Ltda., Lampire Biological Laboratories, Innovative Research Inc, Colorado Serum, SSI Diagnostica, SR Group, Szabo-Scandic, Rockland Immunochemicals, LABone Scientific, Quad Five (Materials Bio Inc.), Guangzhou Ruite Biotechnology, Obio Technology (Shanghai), Beijing Solarbio Science & Technology, and Nanjing SenBeiJia Biological Technology.

Market Segmentation
The Defibrinated Horse Blood market is segmented as below:

By Company

Thermo Fisher Scientific

TCS Biosciences

BioMérieux

E & O Laboratories Ltd

Southern Biological

Biowest (BioNordic A/S)

Pel-Freez Biologicals

Trafalgar Scientific

HemoStat Laboratories

EWC Diagnostics

Dutscher

Serana Europe

Kraeber & Co. GmbH

Bio Nutrientes Do Brasil Ltda.

Lampire Biological Laboratories, Inc.

Innovative Research Inc

Colorado Serum

SSI Diagnostica

SR Group

Szabo-Scandic

Rockland Immunochemicals, Inc.

LABone Scientific Co.Ltd.

Quad Five (Materials Bio Inc.)

Guangzhou Ruite Biotechnology Co., Ltd.

Obio Technology (Shanghai) Corp., Ltd.

Beijing Solarbio Science & Technology Co.,Ltd.

Nanjing SenBeiJia Biological Technology Co., Ltd.

Segment by Volume

50ml

100ml

250ml

500ml

Others

Segment by Application

Biomedicine

Research

Exclusive Industry Outlook
Looking ahead, the convergence of defibrinated horse blood supply with automation in clinical microbiology and expanding diagnostic testing represents a steady growth opportunity. Development of synthetic or animal-free alternatives for certain applications may emerge but is unlikely to fully replace horse blood for specific fastidious organisms. The trend toward laboratory consolidation will favor suppliers with robust quality systems and reliable supply chains. Additionally, the expansion of infectious disease surveillance programs in low- and middle-income countries will create new demand. The ability to offer defibrinated horse blood that combines consistent quality, sterility, and supply reliability—supported by comprehensive documentation and global distribution—will define competitive differentiation.

Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp